Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Coeptis Therapeutics Holdings Inc maintains a gross margin of 65.76%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -230.64%, while the net margin is -188.26%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ZSQR converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ZSQR competes directly with industry leaders such as FLNT and DWSN. With a market capitalization of $668.47M, it holds a leading position in the sector. When comparing efficiency, ZSQR's gross margin of 65.76% stands against FLNT's 26.40% and DWSN's 100.00%. Such benchmarking helps identify whether Coeptis Therapeutics Holdings Inc is trading at a premium or discount relative to its financial performance.
